Opaleye Management Sells $4.77M in Eton Pharmaceuticals Stock
ETON has more than doubled off its 52-week low of $13.76.
Summary
A 10% owner, Opaleye Management Inc., sold $4.77 million of Eton Pharmaceuticals stock, adding to recent insider selling activity as the stock trades near its 52-week high.
Key Events · Ownership and Investor Activity · ETON
-
Significant Share Sale
Opaleye Management Inc., a 10% owner, disposed of 126,685 shares of Eton Pharmaceuticals common stock for a total value of $4,768,637.
-
Profit-Taking Near Highs
The sales occurred between July 2-7, 2026, at prices ranging from $37.39 to $38.37, coinciding with the stock trading near its 52-week high of $38.615.
-
Adds to Distribution Trend
This transaction contributes to a net insider distribution of over $8.6 million in the last 90 days, including a $3.8 million sale by the CEO in May and recent Form 144 filings by other officers.
Analysis · ETON · Life Sciences
Opaleye Management Inc., a 10% owner, sold $4.77 million worth of Eton Pharmaceuticals common stock. This significant sale by a major institutional investor, occurring while the stock trades near its 52-week high, contributes to a broader pattern of insider distribution observed over the past 90 days. While institutional sales can be for portfolio rebalancing, the magnitude of this transaction and the existing selling trend could be interpreted negatively by the market.
At the time of this filing, ETON was trading at $37.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $13.76 to $38.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.